Disease Overview：Rheumatic heart disease（RHD）
Rheumatic heart disease (RHD) is a chronic valvular disorder resulting from repeated episodes of acute rheumatic fever—typically triggered by untreated Group A streptococcal pharyngitis. It predominantly affects the mitral and aortic valves, leading to stenosis, regurgitation, or both, and may progress to heart failure, atrial fibrillation, or systemic embolism if unmanaged. Early diagnosis relies on echocardiography (particularly transthoracic and transesophageal), electrocardiography, and clinical assessment using modified Jones criteria. Management spans medical therapy (e.g., anticoagulation, diuretics, beta-blockers), interventional procedures (balloon valvuloplasty), and surgical interventions—including valve repair or replacement with mechanical or bioprosthetic prostheses. Long-term follow-up and secondary prophylaxis with benzathine penicillin are essential to prevent recurrence.
China offers distinct advantages for RHD treatment: cardiovascular centers in Beijing, Shanghai, and Guangzhou house internationally trained specialists with extensive experience in complex valve surgery and transcatheter interventions. Hospitals deploy state-of-the-art imaging (3T MRI, 4D echocardiography), robotic-assisted platforms, and hybrid operating suites. Clinical outcomes align with global benchmarks—over 95% five-year survival post-mitral valve repair at top-tier institutions, supported by robust registries and peer-reviewed publications. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising quality or safety standards accredited by JCI or CNAS. As a dedicated medical tourism agency, we facilitate seamless care for international patients—curating vetted hospitals, coordinating pre-arrival diagnostics, ensuring transparent all-inclusive pricing, and providing end-to-end support including visa assistance, interpreter services, and postoperative rehabilitation planning.
Rheumatic heart disease: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Rheumatic Heart Disease (Cardiology Department)
Non-Surgical / Conservative Management
*Target Criteria:* Mild-moderate valvular regurgitation/stenosis, NYHA Class I–II, stable rhythm, no heart failure decompensation.
- •Antibiotic Prophylaxis (Penicillin G Benzathine IM): $12–$18 per dose (quarterly); annual cost: $48–$72
- •Diuretics (Furosemide oral): $8–$15/month
- •Beta-blockers (Metoprolol SR): $10–$22/month
- •Anticoagulation (Warfarin + INR monitoring): Drug: $6–$12/month; INR test: $14–$20/test (monthly average: $56–$80)
- •Baseline Workup (per episode): ECG ($12), TTE ($45–$65), BNP ($28), CBC/Cr/electrolytes ($32), ASO/CRP ($24) → Total: $141–$164
Surgical / Interventional Options
*Eligibility:* Severe symptomatic mitral/stenosis regurgitation (NYHA III–IV), LVEF ≥45%, pulmonary artery pressure <60 mmHg, no active rheumatic activity.
- •Mitral Valve Replacement (Mechanical):
- Surgery + ICU stay (5 days): $4,800–$6,200 - Mechanical valve prosthesis (domestic): $1,100–$1,400 - Total: $6,240–$7,910
- •Mitral Valve Repair (Ring annuloplasty):
- Surgery + ICU: $5,100–$6,500 - Annuloplasty ring (domestic): $850–$1,100 - Total: $6,270–$8,010
- •Percutaneous Balloon Mitral Valvuloplasty (PBMV):
- Procedure + fluoroscopy + hospital stay (3 days): $2,900–$3,700 - Inflatable balloon catheter (domestic): $1,300–$1,600 - Total: $4,520–$5,710
Special / Complex Condition Management
- •Combined Valve Disease (e.g., mitral + aortic):
- •Rheumatic Activity Flare + Carditis:
- Repeat echocardiogram + CRP/ESR monitoring: $72–$92
- •Atrial Fibrillation with Thromboembolic Risk:
- Elective cardioversion (if indicated): $1,200–$1,600
Quick Selection Guide
- •<45 years, budget-constrained, isolated MS: PBMV ($4,520–$5,710) — optimal durability and cost-efficiency.
- •45–65 years, severe MR + preserved EF: Valve repair ($6,270–$8,010) — superior long-term survival vs. replacement.
- •>65 years, multiple comorbidities (COPD, CKD): Mechanical AVR + medical optimization ($6,240–$7,910) — avoids anticoagulation complexity of bioprostheses in elderly.
- •NYHA IV + pulmonary hypertension >60 mmHg: Staged medical stabilization (diuretics, PAH-targeted therapy) before re-evaluation — avoid immediate surgery; monthly cost: $220–$310.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Rheumatic heart disease Medical Vacation Packages
Curated transparent all-inclusive packages combining Rheumatic heart disease treatment with China top medical destinations:
